Evidence map›Paper›PMID 26707787›Full record

ArticleJournal of clinical immunology2016

Clinical Features, Non-Infectious Manifestations and Survival Analysis of 161 Children with Primary Immunodeficiency in Mexico: A Single Center Experience Over two Decades.

Saul Oswaldo Lugo Reyes, Guadalupe Ramirez-Vazquez, Alonso Cruz Hernández, Edgar A Medina-Torres, Ana Belen Ramirez-Lopez, Corín España-Cabrera, Citlali A Hernandez-Lopez, Marco A Yamazaki-Nakashimada, Francisco J Espinosa-Rosales, Sara E Espinosa-Padilla and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Saul Oswaldo Lugo ReyesImmunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico. dr.lugo.reyes@gmail.com.
Guadalupe Ramirez-VazquezClinical Immunology Department, National Institute of Pediatrics, Mexico City, Mexico.
Alonso Cruz HernándezClinical Immunology Department, National Institute of Pediatrics, Mexico City, Mexico.
Edgar A Medina-TorresImmunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico.
Ana Belen Ramirez-LopezImmunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico.
Corín España-CabreraClinical Immunology Department, National Institute of Pediatrics, Mexico City, Mexico.
Citlali A Hernandez-LopezImmunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico.
Marco A Yamazaki-NakashimadaClinical Immunology Department, National Institute of Pediatrics, Mexico City, Mexico.
Francisco J Espinosa-RosalesImmunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico.
Sara E Espinosa-PadillaImmunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico.
Chiharu MurataResearch Methodology Department, National Institute of Pediatrics, Mexico City, Mexico. chiharumurata@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe hallmark of Primary immunodeficiencies (PID) is unusual infection, although other immunological non-infectious manifestations such as autoimmunity, allergy and cancer are often present. Most published reports focus on one disease or defect groups, so that a global prevalence of non-infectious manifestations of PID is hard to find. We aimed to describe the clinical features of our pediatric patients with PID, as well as the frequency and evolution of allergy, cancer and autoimmunity.

methodsWe reviewed all the available charts of patients being followed for PID from 1991 to the spring of 2012 at the National Institute of Pediatrics, Mexico City, to describe their demographic, clinical and laboratory features. Their diagnoses were established by pediatric immunologists in accordance to ESID criteria, including routine immunological workup and specialized diagnostic assays. We divided patients by decade of diagnosis to analyze their survival curves.

resultsThere were 168 charts available, from which we excluded one duplicate and six equivocal diagnoses. We studied the charts of 161 PID patients (68% male, 86% alive), mostly from the center of the country, with a positive family history in 27% and known consanguinity in 11%. Eighty percent of the patients were diagnosed during the last decade. Current median age was 124 months; median age at onset of infections, 12 months; median age at diagnosis, 52 months; median age at death, 67.5 months. Severe infection and bleeding were the cause of 22 deaths. Eighty-six percent of all patients had at least one infection, while non-infectious manifestations had a global prevalence of 36%, namely: autoimmunity 19%, allergies 17%, and cancer 2.4%. Survival curves were not significantly different when compared by decade of diagnosis.

conclusionsCompared to other registry reports, we found a lower prevalence of antibody defects, and of associated allergy and cancer. We could only locate two isolated IgA deficiencies and four cases of cancer among our PID patients. Although antibody defects are the most prevalent group (30%), the distribution we found is similar to that reported in Iran, Kuwait, Egypt and Taiwan, with a close 27% share for phagocyte defects, and 26% for the formerly called "well-defined" syndromes. Of note, autoimmune and inflammatory complications are high among our patients with chronic granulomatous disease, as has been reported in both the United States and Japan, but not in Europe.

Indexed as

Autoimmune DiseasesChildConsanguinityFemaleHumansHypersensitivityImmunologic Deficiency SyndromesInfectionsMaleMexicoNeoplasmsPhenotypePrevalenceSurvival AnalysisAllergyAutoimmunitycancerdiagnostic delayinfectioninflammationmexicoprevalenceprimary immunodeficienciessurvivaltreatment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.